**UCI 18-01**
Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

**UCI 18-19**
An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Zhu)

**UCI 18-14**
A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

**UCI 14-25**
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

**UC 15-79**
Ph II Open-Label Randomized Radiosurgery w/ or w/o TT Fields for 1-10 Brain Metastases from NSCLC (Bota)

**OPENING SOON**
For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

1st LINE THERAPEUTIC

NEW DX OF BRAIN METS

BLOOD DRAW ONLY

BASKET

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

PLATINUM-BASED CHEMO TX

FAILED PLATINUM-BASED CHEMO TX

LUNG CANCER
UCI 17-50
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumor (Ou)

UCI 17-90
A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Zhu)

UCI 17-83
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (Zhu)

UCI 15-82
A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease (Ou)

UCI 17-101
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) (Zhu)

UCI 18-18
A Randomized, Double-Blind, Phase 3 study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumor in Metastatic Non-Squamous Non-Small Lung Cancer (NSCLC) Participants (KEYNOTE-789) (Ou)

UCI 07-40
Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

Means Single Mutation Trial

**OPENING SOON**
**Lung Cancer Clinical Trials**

- **UCI 17-81**
  An expanded access protocol for lorlatinib for treatment of patients with advanced non-small cell lung cancer harboring specific molecular alterations (Ou)

- **UCI 16-79 **SUSPENDED**
  A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ejadi)

- **UCI 18-22**
  A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (Ou)

---

- **ALK/ ROS 1**

- **UCI 17-100**
  A Phase ½ Study of alectinib in RET-rearranged non-small cell lung cancer or RETmutated thyroid cancer (Ou)

- **UCI 16-96**
  A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Zhu)

- **UCI 16-79 **SUSPENDED**
  A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) (Ejadi)

---

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**OPENING SOON**

**Means Single Mutation Trial**